MY155646A - Pharmaceutical preparation - Google Patents

Pharmaceutical preparation

Info

Publication number
MY155646A
MY155646A MYPI2011005080A MYPI2011005080A MY155646A MY 155646 A MY155646 A MY 155646A MY PI2011005080 A MYPI2011005080 A MY PI2011005080A MY PI2011005080 A MYPI2011005080 A MY PI2011005080A MY 155646 A MY155646 A MY 155646A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical preparation
compositions
buccal
spray
treatment
Prior art date
Application number
MYPI2011005080A
Other languages
English (en)
Inventor
Ross Calvin John
Booles Clive
Original Assignee
Londonpharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2009/050415 external-priority patent/WO2010122275A1/en
Priority claimed from GB0906971.7A external-priority patent/GB2469791B/en
Application filed by Londonpharma Ltd filed Critical Londonpharma Ltd
Publication of MY155646A publication Critical patent/MY155646A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2011005080A 2009-04-23 2010-04-23 Pharmaceutical preparation MY155646A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB2009/050415 WO2010122275A1 (en) 2009-04-23 2009-04-23 Pharmaceutical preparation
GB0906971.7A GB2469791B (en) 2009-04-23 2009-04-23 Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease

Publications (1)

Publication Number Publication Date
MY155646A true MY155646A (en) 2015-11-13

Family

ID=42244197

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011005080A MY155646A (en) 2009-04-23 2010-04-23 Pharmaceutical preparation

Country Status (23)

Country Link
US (4) US20120157518A1 (enExample)
EP (1) EP2424523B1 (enExample)
JP (1) JP5795760B2 (enExample)
CN (1) CN102395362B (enExample)
AU (1) AU2010240654C1 (enExample)
BR (1) BRPI1014887A8 (enExample)
CA (1) CA2756925A1 (enExample)
DK (1) DK2424523T3 (enExample)
ES (1) ES2390046T3 (enExample)
HR (1) HRP20120711T1 (enExample)
IL (1) IL215453A (enExample)
ME (1) ME02008B (enExample)
MX (1) MX2011010961A (enExample)
MY (1) MY155646A (enExample)
NZ (1) NZ595469A (enExample)
PL (1) PL2424523T3 (enExample)
PT (1) PT2424523E (enExample)
RS (1) RS52430B (enExample)
RU (1) RU2501550C2 (enExample)
SG (1) SG175162A1 (enExample)
SI (1) SI2424523T1 (enExample)
WO (1) WO2010122356A1 (enExample)
ZA (1) ZA201107088B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
CA2756879A1 (en) * 2009-04-23 2010-10-28 Londonpharma Ltd. Sublingual pharmaceutical composition comprising a neutral oil
CA2898113C (en) * 2013-01-14 2022-05-31 Health Clinics Limited Combination cancer therapeutics and uses thereof
US20170326102A1 (en) 2014-11-27 2017-11-16 Cipla Limited Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary Delivery
JP2020033304A (ja) * 2018-08-30 2020-03-05 医療法人ふじいやさか 薬剤又はサプリメント、組成物、及び水素供給器の使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
CH692321A5 (de) * 1997-11-03 2002-05-15 Mepha Ag Pharmazeutisch wirksame Zusammensetzung, welche eine gegen Malariaparasiten wirksame Substanz enthält.
NZ509324A (en) * 1998-07-14 2003-07-25 Bayer Ag Antiparasitic artemisinin derivatives (endoperoxides)
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20060257463A1 (en) * 2002-05-31 2006-11-16 University Of Mississippi Transmucosal delivery of cannabinoids
JP2005529938A (ja) * 2002-06-06 2005-10-06 ユニバーシティ オブ ワシントン 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法
WO2004075921A1 (en) * 2003-02-26 2004-09-10 Vrije Universiteit Brussel Inclusion complex of artemisinin or derivates thereof with cyclodextrins
US20060084675A1 (en) * 2004-10-18 2006-04-20 Thomas Efferth Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor
US20060233895A1 (en) * 2005-04-15 2006-10-19 Brown Paul R Herbal remedy for treating Lyme disease
ATE544444T1 (de) * 2005-10-11 2012-02-15 Yissum Res Dev Co Zusammensetzungen für die nasale abgabe
CN100418524C (zh) * 2005-10-26 2008-09-17 重庆医药工业研究院有限责任公司 一种稳定的青蒿素及青蒿素衍生物的药物组合物

Also Published As

Publication number Publication date
WO2010122356A1 (en) 2010-10-28
SG175162A1 (en) 2011-11-28
US20160022629A1 (en) 2016-01-28
NZ595469A (en) 2013-10-25
EP2424523B1 (en) 2012-06-27
BRPI1014887A2 (pt) 2016-04-19
ZA201107088B (en) 2012-12-27
HK1164140A1 (en) 2012-09-21
AU2010240654B2 (en) 2014-05-08
ES2390046T3 (es) 2012-11-06
EP2424523A1 (en) 2012-03-07
AU2010240654C1 (en) 2014-08-14
US20120157518A1 (en) 2012-06-21
ME02008B (me) 2013-02-28
US20170368023A1 (en) 2017-12-28
RU2011139637A (ru) 2013-05-27
RU2501550C2 (ru) 2013-12-20
PL2424523T3 (pl) 2012-11-30
US20190142737A1 (en) 2019-05-16
SI2424523T1 (sl) 2012-11-30
JP2012524772A (ja) 2012-10-18
HRP20120711T1 (hr) 2012-10-31
IL215453A0 (en) 2011-12-29
CA2756925A1 (en) 2010-10-28
DK2424523T3 (da) 2012-09-24
JP5795760B2 (ja) 2015-10-14
MX2011010961A (es) 2012-04-20
BRPI1014887A8 (pt) 2019-02-12
CN102395362B (zh) 2014-07-02
IL215453A (en) 2014-11-30
CN102395362A (zh) 2012-03-28
RS52430B (sr) 2013-02-28
PT2424523E (pt) 2012-10-03
AU2010240654A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
IN2012DN02805A (enExample)
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
PH12013501567B1 (en) Anti-malarial pharmaceutical composition
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
MY140826A (en) Substituted pyrazoline compounds, their preparation and use as medicaments.
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
PH12013501842A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
MX2011011776A (es) Nuevos profarmacos de triptolite.
WO2007048801A3 (en) Sexual desire enhancing medicaments comprising benzimidazolone derivatives
CR20120084A (es) Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
WO2010089327A3 (en) Indole derivatives as anticancer agents
MX2009011999A (es) Extruidos con enmascaramiento del sabor mejorado.
WO2007009720A3 (en) Prodrugs of pyrazoline compounds, their preparation and use as medicaments
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
MX2011010961A (es) Formula en aspersion sublingual que comprende dihidroartemesinina.
MX367327B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
WO2010122275A8 (en) Pharmaceutical preparation
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
WO2010139411A3 (de) 17β-ALKYL-17α-OXY-ESTRATRIENE
MX2008011017A (es) Compuestos de receptor sigma.